BINCHANG, China, Dec. 13, 2024 /PRNewswire/ -- Developed by Harbin Electric Corporation, the world's first 660 MW high-efficiency ultra-supercritical circulating fluidized bed (CFB) power generation unit, featuring the highest specifications and largest single-unit capacity, installed in the power plant in Binchang, China, has recently successfully completed a 168-hour full-load trial operation test, marking a new global standard in power generation technology.
The Binchang Project, a demonstration initiative endorsed by the Ministry of Science and Technology and the National Energy Administration, stands as a coal industry pacesetter in ecological restoration within the Yellow River Basin. It seamlessly integrates solid waste and mine water utilization with mine geological environment treatment, restoration, and land reclamation.
Planned in two phases, the construction of two units will, upon full operation of the first phase, annually convert approximately 2 million tons of low-calorific value coal and inferior fuels such as coal slime and gangue. It will also utilize 2 million tons of mine water, and supply 6 million GJ of heat, meeting Binzhou City's heating needs and local industrial steam demands.
Additionally, the project will enhance regional power grid stability and electricity supply, addressing local power shortages and fostering sustained socio-economic growth.
Harbin Electric Corporation has engineered the boiler, turbine, and generator, all three core components of the Binchang project. The superior CFB boiler, crafted by Harbin Boiler Company, boasts ultra-low emissions, ultra-high parameters, and ultra-low energy consumption. This fully domestically produced boiler, with its independent intellectual property rights, represents the pinnacle of CFB boiler technology worldwide in terms of parameters and capacity.
The ultra-supercritical indirect air-cooled reverse-flow turbine, a product of Harbin Turbine Company, is another highlight. It is a 660 MW-class turbine featuring a once-through reheat, single-axis, three-cylinder, two-exhaust design. The turbine excels in thermal performance and flow efficiency.
Additionally, the wide-load high-efficiency generator, designed by Harbin Electric Machinery Company, offers high output, exceptional efficiency, low temperature rise, and minimal vibration. It's designed for wide-load operation and outstanding performance under challenging conditions, such as deep peak shaving, leading phase operation, and negative-sequence operation.
The ultra-supercritical CFB power generation technology marks a significant breakthrough under China's 13th Five-Year Plan. It advances high-parameter, large-capacity, and energy-efficient CFB technology, aligning with the nation's new-era energy development objectives. This resonates with Harbin Electric Corporation's dedication to developing new competitive advantages in sustainable, low-carbon energy technologies, and driving the creation of new productive forces to meet the challenges of the evolving energy landscape.
Harbin Electric Corporation utilized resources from China's 13th Five-Year Plan to enter into partnerships with China's top universities, including Tsinghua, Xi'an Jiaotong, Zhejiang, and Chongqing.
Through the integration of advanced technology and practical engineering, they addressed key challenges to engineer ultra-high-parameter, ultra-large CFB boiler equipment, successfully scaling up to 660 MW capacity. The boiler's main steam pressure peaks at 29.3 MPa, equivalent to the weight of four adults standing on a nail-sized section of pipe. With a main steam temperature of 605°C and a reheat steam temperature of 623°C, it sets new international standards for CFB boiler parameters. The boiler also achieves a 95% desulfurization efficiency, enabling ultra-low emissions for large-scale CFB applications.
Harbin Electric Corporation's commitment to excellence has driven the Binchang project from proposal evaluation to national demonstration status under the 13th Five-Year Plan. The success of each phase, from construction and hydrostatic testing to grid connection, and commissioning, has culminated in a world-class power generation facility, boasting unprecedented parameters and performance. The successful operation of the 660 MW ultra-supercritical CFB boiler not only fills a significant gap in global technology but also cements Harbin Electric Corporation's pioneering role in large-capacity, high-parameter CFB technology. This milestone heralds a new era of ultra-supercritical parameters for CFB boilers worldwide.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
The World's First 660 MW Ultra-Supercritical CFB Power Project Commences Operations
The World's First 660 MW Ultra-Supercritical CFB Power Project Commences Operations
The World's First 660 MW Ultra-Supercritical CFB Power Project Commences Operations
Bushu Pharma's ongoing investments and efforts offer customers state-of-the-art capabilities, increased capacity, and innovative solutions, providing top-tier pharmaceutical manufacturing and supply chain management services.
SAN ANTONIO, Dec. 15, 2024 /PRNewswire/ -- Frost & Sullivan researched the contract development and manufacturing organization industry and, based on its analysis, recognizes Bushu Pharmaceuticals (Pharma) with the 2024 APAC Customer Value Leadership Award. The company is a premier contract development and manufacturing organization (CDMO) of pharmaceuticals and medical devices. Renowned for its comprehensive services spanning development to distribution, the company has established itself as a market leader through a strong track record of delivering safe, high-quality products on time and cost-effectively. It leveraged deep domain knowledge, extensive experience, and Good Manufacturing Practices (GMP) certifications from major international regulatory agencies (e.g., United States Food and Drug Administration [FDA], European Medicines Agency, and Pharmaceuticals, and Medical Devices Agency), to establish its robust global presence and supply medicinal products to 56 countries.
Bushu Pharma offers comprehensive services and cutting-edge capabilities to support customers across the product lifecycle, including development, manufacturing, packaging, quality control, regulatory compliance, and supply chain management. The company utilizes its advanced and wide-ranging manufacturing capabilities, extensive specialized facilities, and highly skilled workforce to produce a broad spectrum of pharmaceutical products, ranging from small molecule drugs to complex biologics (including high potency and sterile products). Bushu Pharma excels in managing complex processes, such as product testing and technical transfer (i.e., it ensures consistency, quality, and regulatory compliance when transferring analytical methods, validation processes, and manufacturing procedures from a client's site to its facilities). Its unmatched capabilities ensure consistent delivery of exceptional quality assurance, on-time delivery, and competitive costs, establishing it as a preferred partner in APAC. Bushu Pharma continues to invest in the latest technologies, introducing automated guided forklifts and humanoid dual-arm collaborative robots to enhance efficiency, boost productivity, and ensure high safety and quality standards.
Rubini Kamal, best practices research analyst at Frost & Sullivan, observed, "Bushu Pharma's strategic focus on forging partnerships addresses critical challenges with drug availability and market entry, enhancing its offerings while bridging market gaps and improving healthcare accessibility."
Bushu Pharma prioritizes operational excellence and stringent quality control, establishing itself as a secure, trusted manufacturer in the pharmaceutical space. The Bushu Continuity Plan, a resilient and sustainable business system, operates effectively during large-scale disasters and pandemic conditions to ensure continuous production and supply of pharmaceutical products to patients worldwide. Bushu Pharma's facilities, which have temperature and security monitoring systems, ensure that pharmaceutical products are stored and handled optimally to preserve their efficacy and safety. Real-time monitoring also enhances security measures, preventing unauthorized access and safeguarding sensitive materials. Bushu Pharma enhances customer value through robust environmental sustainability measures, including implementing LED lighting with motion sensors, installing solar panels, transitioning to renewable energy, monitoring wastewater quality, and adopting paper trays and biomass films for packaging at its factories. Bushu Pharma's ongoing commitment to retaining customer trust and delivering value is evident in its global client base of over 95 commercial clients, with 50% of them coming from foreign-affiliated clients. Its steadfast commitment to enhancing services, technologies, and expertise positions Bushu Pharma to lead the CDMO sector into its next growth phase, capturing market share and maintaining its leadership in the years to come.
"Bushu Pharma's innovative GATEWAY to ASIA services streamline market entry for international clients, while strategic partnerships facilitate efficient product distribution and address regional challenges. The company significantly shortens lead times for entering the Asian market, maintains lean inventory levels, and reduces logistics costs and carbon emissions for global pharmaceutical companies compared to traditional supply chains," added Kamal. Bushu Pharma's commitment to operational excellence, environmental sustainability, and employee engagement solidifies its reputation as a trusted and reliable partner. With its strong overall performance, Bushu Pharma earns Frost & Sullivan's 2024 APAC Customer Value Leadership Award in the contract development and manufacturing organization industry.
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company's unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.
Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.
Contact:
Tarini Singh
E: Tarini.Singh@frost.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs
